证券研究报告 | 医药生物 | 2025年11月1日 www.hcza.com 请仔细阅读PPT后部分的分析师声明及免费声明。 华创医药投资观点&研究专题周周谈·第148期 医药行业2025年三季报业绩综述 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 王宏雨 | 执业编号: S0360523080006 邮箱: wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱：zhukechen@hcyjs.com | 本报告由华创证券有限责任公司编制 报告仅供华 ...

Core Viewpoint - The current valuation of the pharmaceutical sector is at a low level, with public funds (excluding pharmaceutical funds) having low allocation to the sector. Considering the positive recovery of macroeconomic factors such as US Treasury rates and the driving effect of large categories and varieties on the industry, the growth of the pharmaceutical industry is expected to remain optimistic through 2025 [10]. Market Review - The CITIC Pharmaceutical Index rose by 0.56%, underperforming the CSI 300 Index by 2.69 percentage points, ranking 27th among CITIC's 30 primary industries [7]. - The top ten stocks by increase this week included Jianfa Zhixin, Te Yi Pharmaceutical, and Bi De Pharmaceutical, while the top ten stocks by decrease included Tuo Jing Life, Xin Nuo Wei, and Shu Tai Shen [7]. Overall View and Investment Themes - The pharmaceutical sector is expected to see a blooming of investment opportunities, particularly in innovative drugs, medical devices, and the innovative chain (CXO + life science services) [10]. - The innovative drug sector is transitioning from quantity logic to quality logic, emphasizing the importance of products that can ultimately generate profits [10]. - The medical device market is witnessing a recovery in bidding volumes, with a focus on home medical devices and orthopedic procurement [10]. - The innovative chain is expected to see a rebound in domestic financing, with a long-term trend towards high growth in the CXO sector [10]. - The pharmaceutical industry is anticipated to enter a new growth cycle, particularly in the specialty raw materials sector, which is currently at a near ten-year low in valuation [10]. Chromatography Industry Focus - Chromatography technology is crucial for the separation and analysis of components in various fields, especially in biopharmaceuticals, where it plays a key role throughout the drug development process [16][19]. - The global biopharmaceutical market is projected to grow from approximately $503 billion in 2023 to $892 billion by 2028, with a compound annual growth rate (CAGR) of 9.5%-12.5% [24]. - The Chinese biopharmaceutical market is also expanding rapidly, with a projected growth from ¥262.2 billion in 2018 to ¥534.8 billion in 2024, reflecting a CAGR of 12.61% [29]. Market Size and Growth - The global chromatography consumables market is expected to grow from $6.9 billion in 2023 to $9 billion by 2026, with a CAGR of 9.26% [37]. - The Chinese chromatography consumables market is projected to grow from ¥11.2 billion in 2023 to over ¥20.3 billion by 2026, with a CAGR of 21.92% [37]. - The global small molecule liquid chromatography market is expected to increase from $3.6 billion in 2021 to $7.7 billion by 2026, with a CAGR of 16.7% [30]. Domestic Industry Dynamics - Domestic chromatography companies are making significant strides in key areas such as chromatography media and industrial chromatography systems, accelerating the process of domestic substitution [44]. - The domestic chromatography media market is currently dominated by foreign companies, but advancements in domestic technology are enhancing competitiveness [44]. - The demand for chromatography products is driven by the need for cost-effective and reliable purification materials in biopharmaceutical production, where purification processes account for a significant portion of production costs [43].

Core Viewpoint - The IVD industry is experiencing rapid growth in domestic product registration and is increasingly focusing on international markets as a second growth curve, driven by domestic replacement and overseas expansion opportunities [13][17][27]. Market Review - The CITIC medical index fell by 2.60%, underperforming the CSI 300 index by 0.37 percentage points, ranking 14th among 30 primary industries [7]. - The top-performing stocks included Asia-Pacific Pharmaceutical, Duorui Pharmaceutical, and Guangsheng Tang, while the worst performers were Beida Pharmaceutical and Hualan Biological [7][11]. Industry and Stock Events - The IVD market is projected to grow significantly, with the global market expected to reach $128.2 billion by 2028, while China's IVD market is anticipated to grow to $8 billion [15][16]. - The registration of IVD products in China has shown robust growth, with a CAGR of 18.6% from 2021 to 2024, particularly in domestic products, which are expected to account for 80.5% of registrations by 2024 [14][17]. Overall Industry Perspective - The current valuation of the pharmaceutical sector is low, with public funds underweighting the sector. The industry is expected to benefit from macroeconomic factors and a recovery in demand for large-scale products [11]. - The domestic innovative drug sector is transitioning from quantity to quality, emphasizing differentiated products and internationalization [11]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment and is expected to benefit from ongoing updates and overseas expansion [11]. IVD Industry Focus - The domestic IVD market is seeing accelerated replacement of imported products, with significant growth in the chemical luminescence segment, which is projected to grow at a CAGR of 15-20% from 2021 to 2025 [35]. - Companies like Mindray and New Industries are making significant strides in overseas markets, focusing on localization and expanding their product lines [32][35]. Company-Specific Developments - Mindray has strengthened its IVD capabilities through strategic acquisitions, enhancing its competitive edge in the international market [32]. - New Industries has successfully established a local operational model in India, which is now being replicated in other key markets, contributing to its overseas revenue growth [32][27]. - Ji'an Medical has rapidly expanded its brand presence in the U.S. market, leveraging its COVID-19 testing products to drive growth [33].

Market Review - The CITIC Pharmaceutical Index decreased by 1.98%, underperforming the CSI 300 Index by 1.54 percentage points, ranking 22nd among 30 CITIC first-level industries [7] - The top ten stocks by increase this week included Xiangrikui, Aopu Mai, and Xinlitai, with increases of 57.86%, 23.89%, and 15.81% respectively [7][37] - The top ten stocks by decrease included Borui Pharmaceutical and Jimin Health, with decreases of 38.36% and 19.65% respectively [7][37] Overall View and Investment Themes - The pharmaceutical sector is currently undervalued, with public funds (excluding pharmaceutical funds) having low allocation to the sector. The company maintains an optimistic outlook for the growth of the pharmaceutical industry in 2025, expecting diverse investment opportunities [12] - The innovative drug sector is transitioning from quantity to quality, focusing on differentiated and internationalized pipelines. Companies that can deliver profitable products are expected to be favored [12] - In the medical device sector, there is a noticeable recovery in bidding volumes for imaging equipment, and home medical devices are benefiting from subsidy policies. The company suggests focusing on key players in these areas [12] - The life sciences service sector is expected to see a rebound in overseas investment and domestic demand, with a focus on CXO and life science services as a growth driver [12] - The pharmaceutical industry is anticipated to enter a new growth cycle, particularly in the specialty raw materials sector, which is expected to benefit from cost improvements and low valuations [12] Industry and Individual Stock Events - The Chinese traditional medicine sector is expected to see growth driven by basic drug reforms and national enterprise reforms, with a focus on companies like Kunming Pharmaceutical Group and Kangyuan Pharmaceutical [10][31] - The medical service sector is expected to improve due to anti-corruption measures and centralized procurement, enhancing the competitiveness of private medical institutions [13][26] - The blood products sector is projected to grow significantly during the 14th Five-Year Plan period, with increased approval for plasma stations and expanding product offerings [13] - The medical device market is experiencing a shift towards domestic alternatives, particularly in high-value consumables and imaging equipment, with significant growth expected in 2024 and beyond [20][21] 2025Q3 Pharmaceutical Performance Outlook - Expected revenue growth rates for various companies in Q3 2025 range from 0% to over 60%, with notable mentions including Bai Pu Sai Si and Kanglong Huacheng [14] - The innovative drug sector is expected to see significant contributions from companies like Betta Pharmaceuticals and Hengrui Medicine, with growth rates projected between 10% and 30% [14] Investment Recommendations - The company recommends focusing on the pharmaceutical retail sector, particularly in light of the accelerating trend of prescription outflow and the optimization of competitive dynamics [25] - In the medical device sector, attention is drawn to companies benefiting from the recovery in bidding for imaging equipment and the growth of home medical devices [20] - The life sciences service sector is highlighted for its potential recovery and growth opportunities, particularly in overseas markets [24]

Core Viewpoint - The article emphasizes that Kanglong Chemical has established itself as a leading global drug research and development service enterprise, with significant growth potential across its various service segments, including laboratory services, small molecule CDMO, clinical CRO, and large molecule and cell gene therapy services [3][4][5]. Group 1: Laboratory Services - The laboratory services segment is the most competitive and currently the primary source of revenue and profit for the company, with expectations for rapid growth driven by competitive advantages in compound design and synthesis [3]. - The biological science services are anticipated to leverage the existing customer base from laboratory chemistry services, leading to sustained high growth in both customer numbers and performance [3]. Group 2: CMC (Small Molecule CDMO) Services - The CMC services are expected to experience rapid growth due to a burgeoning client base and the successful conversion of commercial orders, with a significant increase in the proportion of process validation and commercial orders expected by the first half of 2025 [4]. - The company has established four FDA-approved API commercial production bases across China, the UK, and the US, enabling it to provide innovative drug raw material production solutions globally [4]. Group 3: Clinical CRO Services - The company has completed the establishment of an integrated global clinical CRO service platform, which is expected to enhance efficiency and profitability as industry conditions improve [4]. - The synergy between clinical CRO, preclinical CRO, and CDMO services is anticipated to strengthen further, contributing to accelerated performance [4]. Group 4: Large Molecule and Cell Gene Therapy Services - The company is rapidly advancing its capabilities in large molecule and cell gene therapy services through external resource integration and personnel recruitment, with projected revenue growth of around 10% over the next three years [5]. - This segment is expected to gradually reduce losses, opening up greater long-term growth opportunities for the company [5]. Group 5: Investment Recommendations - The projected net profits for the company from 2025 to 2027 are estimated at 1.689 billion, 1.959 billion, and 2.257 billion yuan, with adjusted net profits of 1.750 billion, 2.122 billion, and 2.438 billion yuan, reflecting year-on-year growth rates of 8.9%, 21.2%, and 14.9% respectively [5]. - The current stock price corresponds to PE ratios of 36, 31, and 27 for 2025-2027, with a recommendation for a higher valuation level based on the company's growth prospects and competitive advantages in the CXO industry [5].

Core Viewpoint - Heng Rui Medicine is positioned as a leading domestic innovative pharmaceutical company, focusing on research, production, and promotion of high-quality drugs, with significant growth potential driven by innovation and internationalization [3][4]. Group 1: Company Overview - Established in 1970, Heng Rui Medicine specializes in oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience [3]. - The company has achieved leading performance and market capitalization in the domestic pharmaceutical sector, despite concerns about future growth [3]. Group 2: Market Dynamics - The peak impact of centralized procurement for generic drugs has passed, with only two products, Sevoflurane and Iodine-131, still facing procurement risks, which are expected to have limited effects [3][4]. - Heng Rui is actively promoting its formulation export business, which is anticipated to become a new growth point for its generic drug operations [3]. Group 3: Innovation and R&D - From 2021 to 2024, Heng Rui is expected to receive approvals for 11 innovative products, including promising drugs like Hecuqipar and Darsylin [4]. - The company’s innovative drug revenue is projected to reach 15.3 billion, 19.2 billion, and 24 billion yuan in 2025, 2026, and 2027 respectively, with a compound annual growth rate exceeding 20% from 2024 to 2027 [4]. Group 4: Internationalization Strategy - Heng Rui's internationalization has evolved from initial formulation exports to overseas clinical trials and licensing agreements, enhancing its global influence [4]. - By mid-2025, the company has initiated 20 clinical trials overseas and is seeking collaborations with leading global pharmaceutical companies [4]. Group 5: Financial Projections - Revenue projections for Heng Rui are 34.57 billion, 37.73 billion, and 43.31 billion yuan for 2025, 2026, and 2027, reflecting year-on-year growth rates of 23.5%, 9.1%, and 14.8% respectively [5]. - The net profit attributable to the parent company is expected to be 9.999 billion, 11.109 billion, and 12.821 billion yuan for the same years, with growth rates of 57.8%, 11.1%, and 15.4% respectively [5].

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong demand, resulting in sustained high growth in sales of domestic new drugs, with several innovative pharmaceutical companies turning losses into profits and entering a stable growth phase [2]. Pharmaceutical Industry Overview - Innovative Drugs: The industry is witnessing a significant increase in the sales of domestic new drugs driven by strong demand, with several companies achieving profitability [2]. - Medical Devices: The high-value consumables sector is seeing mild price reductions, with ongoing domestic substitution and accelerated overseas business progress. The collection and procurement in neurosurgery and neurointervention fields are stabilizing, and new products are expected to drive growth [2]. - Blood Products: The market share is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape. Demand is expected to upgrade towards new products, enhancing industry prosperity [3]. - API (Active Pharmaceutical Ingredients): The end of the capital expenditure peak, combined with three growth drivers, indicates a clear upward turning point for the industry, with leading companies expected to see significant revenue and profit growth [3]. - CXO (Contract Research Organization): The CDMO sector is stabilizing in core business profitability while emerging fields like peptides and ADCs are rapidly growing, enhancing corporate profitability [3]. - Traditional Chinese Medicine and Retail: The hospital sector is recovering, while the retail sector is expected to gradually improve in performance as inventory is digested [3]. Research and Development Trends - The domestic innovative drug business development (BD) is heating up, likely boosting downstream demand recovery. Domestic companies are improving their technology, products, and services, establishing brand effects, and benefiting from the ongoing tariff war with the U.S. [4]. - The research service sector is expected to see improved financial indicators for leading companies due to supply-demand improvements and an upward cycle [4]. Investment Strategy and Market Dynamics - The pharmaceutical industry has published a total of 260 research reports since October 1 of last year, indicating a robust analytical framework and ongoing market engagement [5]. - The medical device sector is expected to see a recovery in performance in the second half of 2025, with ongoing upgrades in product offerings and expansion into overseas markets [2][3]. Summary of Reports and Meetings - The company has conducted numerous offline strategy meetings and expert discussions, indicating active engagement with industry stakeholders and investors [15].

Group 1 - The core viewpoint of the article emphasizes the ongoing developments related to the essential drug catalog, indicating that while the release has been delayed, it is expected to occur soon, with a focus on unique essential drugs that are anticipated to grow faster than non-essential drugs [11][20][21] - The article highlights the performance of the pharmaceutical sector, noting that the CITIC pharmaceutical index fell by 1.98%, underperforming the CSI 300 index by 1.54 percentage points, ranking 22nd among 30 primary industries [8][9] - The article discusses the investment opportunities in the pharmaceutical sector, particularly in traditional Chinese medicine, state-owned enterprise reforms, and the impact of the new medical insurance catalog on OTC companies [11][14][29] Group 2 - The article provides a detailed overview of the essential drug catalog selection process, which includes expert evaluations and consultations to ensure that the selected drugs meet clinical and economic criteria [34] - It presents data on the historical changes in the essential drug catalog, showing a gradual increase in the number of traditional Chinese medicine products included, with a notable shift towards unique products since the 2009 version [17][18] - The article outlines the sales performance of newly included unique essential drugs, indicating significant growth rates for certain products, particularly in the pediatric and respiratory categories [30][32]

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].